Referred to the House Committee on Energy and Commerce.

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

Chamber: United States House of Representatives (The United States of America)
Session: 119th Congress Current

Sponsors

(2)
MD
Maxine Dexter
Democrat · Primary
ML
Michael Lawler
Republican · Primary

Legislative Votes

No votes have been held on this legislation yet.